A Case Study in Scientific Uncertainty, Evidence Assessment, and Institutional Response
This case study draws on multiple evidence streams to analyse institutional responses to tick-associated illness in Australia. It examines Australian Government policy and clinical pathway documents, reports of the Senate Community Affairs References Committee, selected peer‑reviewed literature on tick‑borne disease and Lyme‑like illness, and relevant grey literature, including doctoral thesis material and patient‑advocacy submissions. These sources are treated as distinct evidentiary categories—patient‑reported experience, clinical observation, laboratory findings, pathogen confirmation and epidemiological data—and are analysed with reference to established concepts in science‑policy and institutional decision‑making under uncertainty. The aim is not to resolve contested clinical questions, but to characterise how different forms of evidence have been weighted, integrated, or constrained within Australian tick‑borne disease research and policy frameworks.
Public health systems periodically face conditions in which patients report persistent illness, clinical observations suggest recurring patterns, and diagnostic or pathogen-confirmation evidence remains incomplete or contested. Tick-associated illness in Australia provides a case for examining how institutions respond under such conditions, including how evidence is classified, how uncertainty is managed, and how research priorities are set. Within this broader context, debate regarding Lyme disease has become both a clinical and a policy issue in Australia.
Background
There are four officially recognised tick-borne diseases in Australia, as well as “Debilitating Symptom Complexes Attributable to Ticks” (or DSCATT). In 2018, the Australian Government Department of Health officially replaced the terms “Australian Lyme” and “Australian Lyme-like illness” with DSCATT. A non-diagnostic label, DSCATT is used for “patients presenting with either new-onset or unresolved debilitating symptoms with or without a history of tick bites, and that cannot be attributed to another condition (acute or chronic)”.
Submissions and testimony presented to two Senate Inquiries described patients with symptom profiles reported as consistent with Lyme disease, including reports of positive pathology results from international laboratories. Some submissions also reported that some clinicians had made Lyme disease diagnoses and that patients experienced improvement following treatment. However, these reports are heterogeneous and are not equivalent to standardised epidemiological or controlled clinical evidence.
Australian authorities have acknowledged that tick bites can be associated with serious illness, but maintain that locally acquired classical Lyme disease, caused by the spirochaetal bacterium Borrelia burgdorferi sensu lato, has not been demonstrated to the required evidentiary standard in Australia. Available policy pathway documents do not always make explicit how pathogen-confirmation evidence, patient-reported symptom burden, clinical judgement, and laboratory findings are weighted relative to one another. Where one evidentiary framework is prioritised over others, the criteria for doing so should be explicit, transparent and open to review.
This presents a complex scientific and clinical conundrum, with implications for diagnosis, research, and health policy. It also prompts consideration of whether current research and policy frameworks are sufficiently robust to inform patient care.
Definitional Uncertainty and Its Consequences
A key feature of the Australian response has been the introduction of the term “Debilitating Symptom Complexes Attributed to Ticks” (DSCATT) by the Department of Health in place of the more contested term “Lyme”.
DSCATT appears to function primarily as a syndromic, non-aetiological clinical category for patients with debilitating symptoms, and the DSCATT Clinical Pathway emphasises symptom management. The Pathway also advises against Lyme disease testing in patients who have not travelled outside of Australia, on the basis that tests may produce false-positive results. In the version cited here, the evidentiary basis for that recommendation is not clearly specified.
In a context of uncertainty regarding pathogenicity and diagnosis, however, such findings may still be relevant to further scientific inquiry. The circumstances under which additional investigative approaches might be warranted, including serial testing, broader pathogen screening, or carefully governed therapeutic trials, are not clearly discussed in the available pathway materials.
Prioritising Evidence
A key methodological question is how early findings and associated datasets were incorporated into later scientific reviews. Several analyses of Lyme-like illness in Australia reference initial 1990s studies, while engaging less consistently with the full scope of related doctoral work or grey literature, including thesis material.
From a science-policy perspective, this raises questions about how preliminary findings are weighted once they enter the published record in partial form. Early results may become dominant reference points, while more detailed, subsequent, or less accessible datasets may not be systematically integrated into later reviews.
These are common challenges in complex or contested fields and include difficulty accessing source material, limitations in indexing and retrieval, and differences in how researchers organise and interpret the literature. The DSCATT Clinical Pathway support document titled ‘Literature review to support the debilitating symptom complexes attributed to ticks (DSCATT) clinical pathway’ highlights the importance of comprehensive evidence retrieval and transparent synthesis processes in areas of ongoing scientific uncertainty, particularly where foundational data may sit outside mainstream indexed literature.
Responses to Early Biological Signals
A central question is how early observational findings relate to later research and policy development.
In the early 1990s, research by Dr Michelle Wills reported Borrelia-like organisms in Australian tick samples. These findings were later examined by Professor A Barbour and Dr V Bundoc at the University of Texas Health Science Centre at San Antonio, who concluded that the organisms appeared identical to a European strain of Borrelia.
Because some of the spirochaetes appeared inactive, the scientists treated a sample of genuine European Borrelia afzelii with antibiotics. They then compared the treated B. afzelii with the spiral-shaped, immobile bacteria from Australian ticks, and described the two as identical.
“…the morphology of the antibiotic-treated B. afzelii was indistinguishable from the spiral organisms isolated from the ticks… These findings support the conclusion that the rigid spiral structures isolated from the Australian ticks could be ‘dead’ spirochaetes.”
From a scientific perspective, such findings would generally be treated as preliminary and hypothesis-generating rather than definitive evidence, and the extent to which early signals are incorporated into subsequent research agendas can vary across fields and jurisdictions.
In this case, the early reports do not appear to have been followed by sustained scientific inquiry, as indicated by the sixteen-year research gap after Wills’ publication. Some renewed research activity has been apparent since the 2016 Senate Inquiry, including National Health and Medical Research Council (NHMRC) funding allocated in response to its recommendations.
This invites examination of whether the subsequent research portfolio has been balanced across microbiological, epidemiological, diagnostic, and clinical questions, particularly if interventional research has been narrow in scope.
Government engagement with tick-borne disease stakeholders was initiated in 2013 and has included an initial Scoping Paper to better understand the scientific gaps, two Senate Inquiries and subsequent research funding, but a lack of clarity and consensus persists regarding pathogen diversity, pathogenicity, diagnostics, and clinical relevance in the Australian context.
Ethically, responses to early biological signals should consider the balance between caution, proportionality and responsiveness. While it is appropriate to avoid premature causal attribution, there is also an ethical responsibility to ensure that persistent signals are not indefinitely deferred, creating an ongoing tension between the risks of false positive conclusions and the risks associated with delayed or insufficient inquiry.
Together, these considerations highlight that scientific uncertainty is not only a methodological challenge for institutions, but also an ethical one.
Evidence Gaps and Research Incentives
Organisations such as the Lyme Disease Association of Australia (LDAA) have documented patient experiences and advocated for government intervention. These materials may provide a useful source of patient-reported and service experience data, although they differ methodologically from peer-reviewed epidemiological or clinical research, and may be underused in formal evidence synthesis.
In this case, the absence of definitive evidence for locally acquired Lyme disease in Australia is treated, in practical policy terms, as a sufficient basis for non-recognition. In emerging or complex disease contexts, and when relevant research has been limited and inconclusive, this interpretation may be premature and may become a barrier to further investigation and patient care.
Scientific research operates within funding, publication, and career incentive structures that tend to favour:
- Clearly defined hypotheses
- Established methodologies
- Lower risk, consensus-aligned research questions
Exploratory work – such as broad-spectrum pathogen discovery or investigation of atypical clinical presentations – can be more difficult to fund, standardise, and publish.
This creates the possibility of a feedback loop in which limited investigation and marginalisation of evidence reinforce initial uncertainty, which in turn justifies continued limitation of research scope.
Premature Conclusions or Exclusions?
Which mechanism or authority should determine the adequacy of the research base, or the point at which it is sufficient to justify exclusions or conclusions?
“The Government will consider the findings of current research, including the CSIRO’s findings that after extensive research, no Lyme disease-causing Borrelia species was found in Australia. Any future investment and potential research will build on the evidence available, rather than further exploring Borrelia as a vector for DSCATT in Australia.”
(Australian Government Response to the Senate Community Affairs References Committee report: Access to diagnosis and treatment for people in Australia with tick-borne diseases)
Consensus is generally understood as the result of converging evidence across multiple studies; however, it is not clear from the available material whether the Government explicitly evaluated the broader scientific consensus before making a decision that will shape the future direction of scientific inquiry.
In this context, a decision to deprioritise Borrelia-focused investigation could be seen as contestable, given the limited extent of the existing literature and the persistence of unresolved diagnostic questions. In a context characterised by substantial scientific uncertainty, the absence of a robust evidence base does not itself justify discontinuing investigation; rather, it indicates the need for further systematic inquiry.
From this perspective, the decision may be interpreted as favouring definitional closure in advance of more complete epidemiological and clinical characterisation.
Policy Stability and Path Dependence
Public health policy tends to prioritise stability and consistency. Once a position is established – particularly in areas involving contested evidence – it can become embedded across multiple levels of the system, including:
- Clinical guidelines
- Educational curricula
- Public health messaging
Revising such positions requires not only new evidence but also institutional willingness to reassess prior assumptions. This introduces elements of path dependence, whereby initial interpretations may shape subsequent research priorities, guideline development, and the practical scope of scientific review.
Ethics and Governance Frameworks
When science is inconclusive, Australian medicine is guided by professional standards that emphasise evidence-informed decision-making, clinical judgement, patient safety, and ongoing review as the evidence base develops. Or more specifically, professional conduct codes, clinical guidelines, and regulatory supervision frameworks.
The available documentation does not always clearly explain the justification for limiting the role of clinical judgement, narrowing accepted evidence inputs, or prioritising symptom management in the absence of diagnostic information.
The DSCATT Clinical Pathway can be interpreted as setting a threshold for recognising locally acquired Lyme disease that is difficult to satisfy, because it relies heavily on epidemiological confirmation that is currently limited, together with laboratory evidence that is not consistently accepted in this context.
Under that interpretation, the framework may limit opportunities to generate the very evidence required for later confirmation.
In cases where patients present with complex, non-specific symptoms but lack recognised diagnostic confirmation, clinicians may face a constrained set of options. These constraints are not necessarily the result of individual decisions, but of systemic factors including:
- Professional standards and oversight
- Medico-legal considerations
- Availability of validated diagnostic tools
Under such conditions, clinical conservatism may be a rational response. This may justify a mechanism for capturing patient presentations that remain insufficiently explained and emerging diseases that may slip under the radar.
Interpreting the Australian Case
The Australian experience with tick-borne illness highlights several features of systems operating under scientific and clinical uncertainty:
- The tension between patient-reported experience and formally recognised evidence
- The influence of definitions on research trajectories
- The role of incentives in shaping scientific inquiry
- The stabilising, and sometimes constraining, effects of policy frameworks
These features are consistent with well-described behaviours in complex institutional systems.
Conclusion
Lyme disease in Australia, and the institutional response to date, provides a contemporary case study of how scientific uncertainty is managed in practice. More broadly, it illustrates how systems respond when the available evidence is incomplete, contested, and evolving.
In most organisations, decisions are embedded in feedback loops that connect indicators, incentives, and authority structures. These loops determine which signals influence decisions.
The Australian tick-borne disease debate may therefore be understood not only as a scientific disagreement but also as a case in which institutional evidence selection and weighting processes may have become relatively resistant to revision. Evidence types that do not align readily with pathogen confirmation models, including patient-reported symptom clusters and front-line clinical observations, appear to have had limited influence on research scope and policy development. For researchers, clinicians, and policymakers alike, the challenge is not only to build a more robust evidence base but also to ensure that the structures governing inquiry remain sufficiently open to accommodate it. In this context, institutions seeking to improve health outcomes may need to remain open to revising established assumptions when new evidence emerges, even where doing so introduces institutional uncertainty. Systems that are resistant to revisiting established assumptions may be less able to correct reinforcing feedback loops accommodate or adapt to emerging evidence, even where the human consequences are substantial.
References
- Wills, M. (1990s). Lyme Borreliosis: The Australian Perspective (Doctoral thesis). Southern Cross University / University of Newcastle repository. https://hdl.handle.net/1959.13/1350473
- Commonwealth Department of Health (2013). Scoping Study to develop a research project(s) to investigate the presence or absence of Lyme disease in Australia (Prof John Mackenzie report, Clinical Advisory Committee on Lyme Disease). Australian Government. https://web.archive.org/web/20140212162154/http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-lyme-disease.htm/$File/scoping-study-2013.pdf
- Commonwealth Department of Health (2016). Lum, G. Does Lyme disease exist in Australia? Australian Government Department of Health publication.
- Beaman, M. (2016). Lyme disease: why the controversy? Professional commentary / published article. https://www.researchgate.net/publication/309728410_Does_Lyme_disease_exist_in_Australia
- Graves, S. et al. (2016). Is there a Lyme-like disease in Australia? Summary of findings to date. Technical review publication. https://www.sciencedirect.com/science/article/pii/S2352771416300039
- Australian Senate Standing Committee on Community Affairs (2025). Access to diagnosis and treatment for people in Australia with tick-borne diseases. https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Tick-bornediseases/Report
- Debilitating symptom complexes attributed to ticks (DSCATT) clinical pathway https://www.cdc.gov.au/resources/publications/debilitating-symptom-complexes-attributed-ticks-dscatt-clinical-pathway
Access note: Some early research outputs referenced in this paper, including doctoral thesis material and related studies, are classified as grey literature and may not be consistently indexed in mainstream journal databases. Where possible, original repository or institutional copies have been cited directly.
2026: Australian 18mo child with multiple bullseye rashes 48 hours post tick bite
